Healthcare - Biotechnology - NASDAQ - US
$ 3.03
-19.8 %
$ 148 M
Market Cap
-1.59
P/E
CASH FLOW STATEMENT
-53.5 M
OPERATING CASH FLOW
-22.5 M
INVESTING CASH FLOW
188 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cabaletta Bio, Inc.
| Net Income | -67.7 M |
| Depreciation & Amortization | 1.43 M |
| Capital Expenditures | -687 K |
| Stock-Based Compensation | 11.3 M |
| Change in Working Capital | 101 K |
| Others | -318 K |
| Free Cash Flow | -54.2 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (67.7) | (53.0) | (46.3) | (33.3) | (16.9) | (12.2) | (0.3) |
| Depreciation & Amortization | 1.4 | 1.2 | 0.7 | 0.4 | 0.1 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (2.3) | 0 | 0 |
| Stock Based Compensation | 11.3 | 6.9 | 5.8 | 4.4 | 2.3 | 0.6 | 0 |
| Other Operating Activities | 1.3 | 2.8 | 62 K | 0.1 | 2.3 | 7.4 | 0.3 |
| Change in Working Capital | 0.1 | (4.3) | 5.6 | 1.7 | (1.5) | (0.5) | 81.3 K |
| Cash From Operations | (53.5) | (46.4) | (34.1) | (26.8) | (16.0) | (4.7) | 0 |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (0.7) | (2.5) | (1.2) | (0.6) | (0.7) | 0 | 0 |
| Other Items | (21.8) | (24.8) | 7.2 | (7.3) | 0 | 0 | 0 |
| Cash From Investing Activities | (22.5) | (27.2) | 6.0 | (8.0) | (0.7) | 0 | 0 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | (0.2) | 0 | (0.2) | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 12.5 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | (10.1) | 0 | 0 |
| Other Financing Activities | 2.4 | 0.1 | 0.7 | 0.2 | 58.8 | 25.1 | 1.33 K |
| Cash From Financing Activities | 187.6 | 33.0 | 48.9 | 24 K | 119.9 | 37.7 | 1.33 K |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 111.6 | (40.6) | 20.8 | (34.8) | 103.2 | 33.0 | 1.33 K |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (54.2) | (48.8) | (35.3) | (27.4) | (16.7) | (4.7) | 0 |